{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T19:45:56Z","timestamp":1793562356928,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T00:00:00Z","timestamp":1295222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite their efficacy in myeloma, corticosteroids have acute and chronic toxicities. Newer agents with significant anti\u2010myeloma activity permit the development of steroid\u2010free regimens. We designed a Phase II clinical trial to study the toxicity and efficacy of a steroid\u2010free combination of bortezomib and thalidomide as a first\u2010line treatment in patients with symptomatic myeloma. Patients received bortezomib 1\u00b73\u2003mg\/m<jats:sup>2<\/jats:sup> on days 1, 4, 8 and 11 every 21\u2003d and thalidomide 150\u2003mg\/d for a maximum of eight cycles. Amongst 27 evaluable patients, the overall response was 81\u00b75% with 25\u00b78% near complete response or greater. The response rate was comparable to most other two drug combinations for upfront therapy but lower than that obtained with the use of three drugs. The most common grade 3 toxicities were peripheral neuropathy (22%), pneumonia (15%), fatigue (7%) and anaemia (7%). Peripheral neuropathy completely resolved in 80% of the patients upon completion of therapy, but not in the remaining 20% of patients. No venous thromboembolic events were observed even in the absence of prophylactic anticoagulation. The median progression\u2010free survival was 16\u00b78\u2003months (95% confidence interval 8\u00b77\u201321\u00b76\u2003months). Median overall survival has not yet been reached at a median follow up of 39\u2003months. The 3\u2010year overall survival was 74%. This study demonstrates: (i) the efficacy of a steroid\u2010free regimen; (ii) mostly reversible treatment\u2010related peripheral neuropathy; and (iii) the absence of venous thrombotic events.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08534.x","type":"journal-article","created":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T03:43:20Z","timestamp":1295322200000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma"],"prefix":"10.1111","volume":"152","author":[{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,17]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams J.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_5_3_1","first-page":"826","article-title":"First\u2010line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo M.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_4_1","first-page":"73","article-title":"Bortezomib (Velcade(R))\u2010thalidomide\u2010dexamethasone (VTD) vs thalidomide\u2010dexamethasone (TD) in preparation for autologous stem\u2010cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"110","author":"Cavo M.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_5_1","first-page":"351","article-title":"A phase III study of double autotransplantation incorporating bortezomib\u2010thalidomide\u2010dexamethasone (VTD) or thalidomide\u2010dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD","volume":"114","author":"Cavo M.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2008.00193.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V110.11.3595.3595","article-title":"Bortezomib with high\u2010dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high\u2010dose therapy","volume":"110","author":"Corso A.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3017"},{"key":"e_1_2_5_10_1","first-page":"3887","article-title":"The weekly infusion of bortezomib reduces peripheral neuropathy","volume":"114","author":"Gay F.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_11_1","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau J.L.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"139a","DOI":"10.1182\/blood.V110.11.450.450","article-title":"VELCADE\/Dexamethasone (Vel\/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005\/01 trial","volume":"110","author":"Harousseau J.L.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_5_13_1","first-page":"354","article-title":"Bortezomib plus dexamethasone (VD) versus reduced\u2010dose bortezomib plus thalidomide plus dexametasone (vTD) as induction treatment prior to autologous stem\u2010cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM)","volume":"114","author":"Harousseau J.L.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05540.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"238a","DOI":"10.1182\/blood.V108.11.796.796","article-title":"Longterm follow up of patients treated with bortezomib alone or in combination with dexamethasone as frontline therapy for multiple myeloma","volume":"108","author":"Jagannath S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_5_16_1","first-page":"3605","article-title":"Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma","volume":"110","author":"Kaufman J.L.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169565"},{"key":"e_1_2_5_18_1","first-page":"3","article-title":"A prospective, multicenter, randomized, trial of bortezomib\/melphalan\/prednisone (VMP) versus bortezomib\/thalidomide\/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib\/thalidomide (VT) versus bortezomib\/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65\u2003years","volume":"114","author":"Mateos M.\u2010V.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3323"},{"key":"e_1_2_5_26_1","first-page":"405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel M.J.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_5_28_1","first-page":"618","article-title":"Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide (VDT), an effective steroid independent regimen for previously untreated multiple myeloma patients: final result of a phase II study","volume":"114","author":"Sher T.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701214236"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08534.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08534.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:19:11Z","timestamp":1697375951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08534.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,17]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08534.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08534.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,17]]},"assertion":[{"value":"2011-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}